A 0.5 mg dose of colchicine, a drug commonly used for conditions such as gout, was recently approved by the FDA to prevent cardiovascular events in patients with residual inflammatory risk.It is the first anti-inflammatory agent to be approved as an atheroprotective CV treatment, according to a press release from the manufacturer, and is expected to be available later this year. News of the